SMT201500245B - Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso - Google Patents
Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stessoInfo
- Publication number
- SMT201500245B SMT201500245B SM201500245T SM201500245T SMT201500245B SM T201500245 B SMT201500245 B SM T201500245B SM 201500245 T SM201500245 T SM 201500245T SM 201500245 T SM201500245 T SM 201500245T SM T201500245 B SMT201500245 B SM T201500245B
- Authority
- SM
- San Marino
- Prior art keywords
- irinotecan
- liposome
- preparation process
- respective hydrochloride
- hydrochloride
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title 1
- 229960004768 irinotecan Drugs 0.000 title 1
- 239000002502 liposome Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2009/075298 WO2011066684A1 (zh) | 2009-12-03 | 2009-12-03 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201500245B true SMT201500245B (it) | 2015-10-30 |
Family
ID=44114598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201500245T SMT201500245B (it) | 2009-12-03 | 2015-10-09 | Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20120282325A1 (it) |
| EP (1) | EP2508170B1 (it) |
| JP (1) | JP5645954B2 (it) |
| KR (2) | KR20120089754A (it) |
| CN (1) | CN102271659B (it) |
| AU (1) | AU2009356132B2 (it) |
| BR (1) | BR112012012151B8 (it) |
| CA (1) | CA2782911C (it) |
| CY (1) | CY1116811T1 (it) |
| DK (1) | DK2508170T3 (it) |
| ES (1) | ES2547698T3 (it) |
| HR (1) | HRP20150911T1 (it) |
| HU (1) | HUE027467T2 (it) |
| MX (1) | MX2012005775A (it) |
| PL (1) | PL2508170T3 (it) |
| PT (1) | PT2508170E (it) |
| RU (1) | RU2526114C2 (it) |
| SI (1) | SI2508170T1 (it) |
| SM (1) | SMT201500245B (it) |
| WO (1) | WO2011066684A1 (it) |
| ZA (1) | ZA201203316B (it) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102935066B (zh) * | 2011-08-16 | 2014-09-17 | 齐鲁制药有限公司 | 一种伊立替康脂质体制剂及其制备方法 |
| DK2768484T3 (da) | 2011-10-21 | 2019-10-07 | Jazz Pharmaceuticals Res Llc | Lyofiliserede liposomer |
| KR101842279B1 (ko) * | 2012-03-29 | 2018-03-26 | 우석대학교 산학협력단 | 이리노테칸의 안정성증진을 위한 주사제용 조성물 |
| KR20140143838A (ko) * | 2012-04-10 | 2014-12-17 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 비스-중합체 지질-펩티드 콘주게이트 및 이들의 나노입자 |
| US9949927B2 (en) | 2012-04-10 | 2018-04-24 | The Regents Of The University Of California | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| CN102697720B (zh) * | 2012-06-29 | 2014-01-15 | 海南灵康制药有限公司 | 盐酸伊立替康脂质纳米粒注射剂 |
| CN103181898B (zh) * | 2012-11-23 | 2016-03-09 | 杭州师范大学 | 一种奥沙利铂脂质体及其应用 |
| EA023079B1 (ru) * | 2012-12-24 | 2016-04-29 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения липосомальной формы иринотекана (варианты) |
| CN104906586A (zh) * | 2014-03-10 | 2015-09-16 | 中国科学院上海药物研究所 | 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用 |
| LT3138555T (lt) | 2014-04-30 | 2021-03-25 | Fujifilm Corporation | Liposomų kompozicija ir jų gamybos būdas |
| US10098813B2 (en) * | 2014-09-03 | 2018-10-16 | Sun Pharmaceutical Industries Limited | Perfusion dosage form |
| CN105796495B (zh) * | 2014-12-29 | 2020-10-23 | 南京绿叶制药有限公司 | 一种盐酸伊立替康脂质体药物组合物及其制备方法 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| WO2016208742A1 (ja) * | 2015-06-25 | 2016-12-29 | 参天製薬株式会社 | 注射剤 |
| KR20180037210A (ko) | 2015-08-20 | 2018-04-11 | 입센 바이오팜 리미티드 | 암 치료를 위한 리포좀 이리노테칸 및 parp 저해제를 이용하는 조합요법 |
| KR102714060B1 (ko) | 2015-08-21 | 2024-10-08 | 입센 바이오팜 리미티드 | 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 |
| NZ741291A (en) | 2015-10-16 | 2022-10-28 | Ipsen Biopharm Ltd | Stabilizing camptothecin pharmaceutical compositions |
| ES2968415T3 (es) | 2016-02-09 | 2024-05-09 | Sun Pharmaceutical Ind Ltd | Sistema de perfusión |
| CN107281102A (zh) * | 2016-04-11 | 2017-10-24 | 江苏竞诺择生物医药科技有限公司 | 一种用于结直肠肿瘤治疗的药物微粒组合物 |
| CN107456456A (zh) * | 2016-06-03 | 2017-12-12 | 江苏恒瑞医药股份有限公司 | 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途 |
| JP6878473B2 (ja) * | 2016-06-28 | 2021-05-26 | キメリックス インコーポレイテッド | ブリンシドフォビルの製剤 |
| CN106109415B (zh) * | 2016-07-26 | 2019-01-29 | 金华市人民医院 | 一种载喜树碱类抗肿瘤药物脂质体、制备方法及其应用 |
| RU2756837C2 (ru) * | 2016-09-09 | 2021-10-06 | Айрисис, Инк. | Липосомальные противоопухолевые композиции |
| IL266198B2 (en) * | 2016-10-28 | 2023-11-01 | Servier Lab | Liposomal formulation for use in cancer treatment |
| WO2018083470A1 (en) | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| WO2019244978A1 (ja) | 2018-06-20 | 2019-12-26 | 富士フイルム株式会社 | ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| CN109675047B (zh) * | 2019-01-07 | 2020-12-04 | 中国科学院化学研究所 | 一种对具有游离羟基的化合物进行脂质体修饰的方法 |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
| US12195755B2 (en) | 2019-05-20 | 2025-01-14 | Brown University | Placental lipid bilayer for cell-free molecular interaction studies |
| US11273124B2 (en) * | 2019-05-23 | 2022-03-15 | Brown University | Antifungal nanoparticles for targeted treatment of fungal infections |
| US12509559B2 (en) | 2019-10-28 | 2025-12-30 | Brown University | Bacterial beta-lactamase responsive hydrogels |
| CN114177278A (zh) * | 2021-10-18 | 2022-03-15 | 山东多美康生物医药有限公司 | 脂质体制备 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6740335B1 (en) * | 1997-09-16 | 2004-05-25 | Osi Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
| US6355268B1 (en) * | 1998-09-16 | 2002-03-12 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
| PT1443900E (pt) * | 2001-11-13 | 2012-08-01 | Celator Pharmaceuticals Inc | Composições de veículo lipídico com estabilidade melhorada no sangue |
| KR101223366B1 (ko) * | 2004-05-03 | 2013-01-16 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
| WO2005117878A1 (ja) * | 2004-06-01 | 2005-12-15 | Terumo Kabushiki Kaisha | イリノテカン製剤 |
| CN1326525C (zh) * | 2004-11-26 | 2007-07-18 | 复旦大学 | 10-羟基喜树碱长循环脂质体及其冻干制剂 |
| WO2007076117A2 (en) * | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| US7489990B2 (en) * | 2006-07-17 | 2009-02-10 | Fehr Stephen L | Systems and methods for calculating and predicting near term production cost, incremental heat rate, capacity and emissions of electric generation power plants based on current operating and, optionally, atmospheric conditions |
| CN101019834A (zh) * | 2006-12-31 | 2007-08-22 | 西安力邦医药科技有限责任公司 | 注射用7-乙基-10羟基喜树碱脂质体的制备方法 |
| CN1994279A (zh) * | 2006-12-31 | 2007-07-11 | 西安力邦医药科技有限责任公司 | 注射用盐酸伊立替康脂质体的制备方法 |
| CA2681302C (en) | 2007-03-19 | 2013-07-23 | Dhiraj Khattar | Proliposomal and liposomal compositions of poorly water-soluble compounds |
| CN101283983A (zh) * | 2007-10-26 | 2008-10-15 | 南京长澳医药科技有限公司 | 一种稳定的喜树碱类药物脂质体组合物 |
-
2009
- 2009-12-03 ES ES09851784.0T patent/ES2547698T3/es active Active
- 2009-12-03 DK DK09851784.0T patent/DK2508170T3/en active
- 2009-12-03 HR HRP20150911TT patent/HRP20150911T1/hr unknown
- 2009-12-03 SI SI200931279T patent/SI2508170T1/sl unknown
- 2009-12-03 PT PT98517840T patent/PT2508170E/pt unknown
- 2009-12-03 HU HUE09851784A patent/HUE027467T2/en unknown
- 2009-12-03 WO PCT/CN2009/075298 patent/WO2011066684A1/zh not_active Ceased
- 2009-12-03 EP EP09851784.0A patent/EP2508170B1/en active Active
- 2009-12-03 US US13/512,048 patent/US20120282325A1/en not_active Abandoned
- 2009-12-03 KR KR1020127015958A patent/KR20120089754A/ko not_active Ceased
- 2009-12-03 MX MX2012005775A patent/MX2012005775A/es active IP Right Grant
- 2009-12-03 RU RU2012123875/15A patent/RU2526114C2/ru active
- 2009-12-03 JP JP2012541296A patent/JP5645954B2/ja not_active Expired - Fee Related
- 2009-12-03 CN CN2009801540269A patent/CN102271659B/zh active Active
- 2009-12-03 CA CA2782911A patent/CA2782911C/en active Active
- 2009-12-03 KR KR1020167033432A patent/KR101780915B1/ko not_active Expired - Fee Related
- 2009-12-03 BR BR112012012151A patent/BR112012012151B8/pt not_active IP Right Cessation
- 2009-12-03 PL PL09851784T patent/PL2508170T3/pl unknown
- 2009-12-03 AU AU2009356132A patent/AU2009356132B2/en not_active Ceased
-
2012
- 2012-05-08 ZA ZA2012/03316A patent/ZA201203316B/en unknown
-
2015
- 2015-10-09 SM SM201500245T patent/SMT201500245B/it unknown
- 2015-10-21 CY CY20151100943T patent/CY1116811T1/el unknown
-
2017
- 2017-03-21 US US15/464,922 patent/US10022365B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201500245B (it) | Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso | |
| PL2990421T3 (pl) | Przeciwciała anty-ceacam1 oraz sposoby ich stosowania | |
| PL2427212T3 (pl) | Przeciwciała anty cd-100 i sposoby ich zastosowania | |
| GB2471765B (en) | Geopolymeric structural building units and methods of manufacture thereof | |
| HUE036439T2 (hu) | Antimikrobiális készítmények és azok alkalmazási módszerei | |
| DK2419670T3 (da) | Leveringsmetode og sammensætninger | |
| PL3121280T3 (pl) | Antysensowne kompozycje i sposoby ich wytwarzania i stosowania | |
| EP2470485A4 (en) | CERAMIC ISOLATOR AND METHODS OF USE AND MANUFACTURE | |
| PL2299977T3 (pl) | Liposomy do dostarczania leków i sposoby ich wytwarzania | |
| IL232598A0 (en) | Crystalline forms of vilzodone and vilzodone hydrochloride | |
| EP2128240A4 (en) | ALCOHOLIC BEVERAGE CONTAINING TOMATO JUICE AND PROCESS FOR PRODUCING THE SAME | |
| DK2415800T3 (da) | Hyperforgrenet polyoxyalkylenforbindelse og fremgangsmåde til deres fremstilling | |
| BRPI0819704A2 (pt) | Branqueador líquido estável em prateleira e processo de preparação deste | |
| PT2504298T (pt) | Preparação e purificação de iodoxanol | |
| IL221991B (en) | Polymorphic forms st-246 and methods of preparation | |
| IL197655A0 (en) | Emulsions and methods of their production | |
| EP2408153A4 (en) | FIRST RELAY SERVER AND SECOND RELAY SERVER | |
| BR112014002804A2 (pt) | revestimento e método de preparação do mesmo | |
| CU24148B1 (es) | Intermedios de agomelatina y método de preparación de éstos | |
| FI20105638A0 (fi) | Kivipinnoitteen valmistus | |
| IT1397894B1 (it) | Dispositivo micromeccanico e procedimento per la produzione dello stesso | |
| IT1394217B1 (it) | Metodo di preparazione di fesoterodina e/o fesoterodina fumarato. | |
| IT1403286B1 (it) | Procedimento per la preparazione di compresse comprendenti 5-idrossitriptofano e triptofano | |
| IL219316A0 (en) | Processes for the preparation of 5-lipooxygenase activating protein inhibitors and their intermediates | |
| EP2467375A4 (en) | FORMS OF DEXLANDSOPRAZOLE AND METHOD OF MANUFACTURING THEREOF |